3-way competition among Boehringer, Astra & MSD over new antidiabetic complexes

In the Korean diabetes treatment market, a 3-way competition is expected among complexes in combination with DPP-4 and SGLT-2 inhibitors.

According to MSD, ‘ertugliflozin,’ a SGLT-2 inhibitor jointly being developed by MSD and Pfizer, was confirmed to drop down blood sugar when additionally administered with the combination therapy of ‘Januvia(generic name: sitagliptin)’ and metformin at the r...